Bristol To Sell Oncology Distribution Unit Ahead Of Medicare Part B Changes
This article was originally published in The Pink Sheet Daily
The company has signed an agreement to sell its Oncology Therapeutics Network to One Equity Partners, Bristol announces. The transaction is expected to close during the first quarter of 2005.
You may also be interested in...
CMS expects the shift from average wholesale price-based reimbursement to the ASP plus 6% formula to generate savings of $530 mil. to Medicare and $270 mil. to beneficiaries in 2005. The agency expects changes outlined in its proposed rule to bring “transparency and appropriateness” to its payments for Part B drugs.
The cancer care services company has worked out a $1.7 bil. buyout deal, but can actively solicit other offers until April 16. By going private, U.S. Oncology avoids wide fluctuations in its share price and possible future cuts in reimbursement.
Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.